Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, China.
Front Immunol. 2022 Jun 3;13:886045. doi: 10.3389/fimmu.2022.886045. eCollection 2022.
Group 2 innate lymphoid cells (ILC2s) are important mediators of type 2 immunity and play an important role in allergic diseases, helminth infections, and tissue fibrosis. However, the role of ILC2s in tumor immunity requires further elucidation. Studies over the past decade have reported that ILC2s play a promoting or suppressing role in different tumors. Here we reviewed the role of ILC2s in solid tumors demonstrating that ILC2s act as a crucial regulator in tumor immunity. We proposed that ILC2s could be an important predictor for tumor prognosis and a new therapeutic target after immunotherapy resistance. In conclusion, our study shed new light on modifying and targeting ILC2s for anti-tumor immunotherapy.
2 型固有淋巴细胞 (ILC2s) 是 2 型免疫的重要介质,在过敏疾病、寄生虫感染和组织纤维化中发挥重要作用。然而,ILC2s 在肿瘤免疫中的作用需要进一步阐明。过去十年的研究报告称,ILC2s 在不同的肿瘤中发挥促进或抑制作用。在这里,我们综述了 ILC2s 在实体瘤中的作用,表明 ILC2s 是肿瘤免疫中的一个关键调节因子。我们提出,ILC2s 可能是肿瘤预后的一个重要预测因子,也是免疫治疗耐药后的一个新的治疗靶点。总之,我们的研究为抗肿瘤免疫治疗中修饰和靶向 ILC2s 提供了新的思路。